Myostatin Inhibitor vs YK-11
A side-by-side research comparison of Myostatin Inhibitor and YK-11 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Myostatin Inhibitor | YK-11 |
|---|---|---|
| Full name | Myostatin Inhibitor Peptides (Anti-GDF-8) | YK-11 (Myostatin Inhibitor / SARM) |
| Category | Muscle Growth | Muscle Growth |
| Status | Research compound | Research compound |
| Mechanism | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. | Partial androgen receptor agonist that induces follistatin expression, creating dual myostatin inhibition and AR activation. |
| Molecular weight | 2,000-15,000 Da (varies) | 430.54 Da |
| Half-life | 4-48 hours (design-dependent) | ~6-10 hours |
| Bioavailability | Variable (SubQ) | ~70% oral |
| Typical dose | 50-500 mcg | 5-10 mg |
| Frequency | 3-7x per week | Once daily |
| Route | Subcutaneous | Oral |
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
YK-11 reported benefits
- Dual anabolic mechanism
- Follistatin induction
- Oral convenience
- Muscle hardening
Related comparisons
Research and educational reference only. Not medical advice.